

Chester Costales

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11050412/publications.pdf>

Version: 2024-02-01

14
papers

462
citations

623734

14
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

442
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 404-415.	4.7	21
2	Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 646-657.	4.7	30
3	Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1018-1031.	2.5	22
4	A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker. <i>Analytical Chemistry</i> , 2020, 92, 9745-9754.	6.5	24
5	Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7). <i>Biochemical Pharmacology</i> , 2020, 174, 113829.	4.4	22
6	Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 634-642.	2.5	41
7	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: α -SLC-Phenotyping-Using Primary Human Hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 72-83.	2.5	58
8	Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 390-398.	2.5	35
9	<i>In vitro</i> studies with two human organic anion transporters: OAT2 and OAT7. <i>Xenobiotica</i> , 2018, 48, 1037-1049.	1.1	18
10	Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1200-1211.	3.3	19
11	Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1179-1189.	3.3	34
12	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes. <i>AAPS Journal</i> , 2017, 19, 787-796.	4.4	39
13	IMI "Oral biopharmaceutics tools project" Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 610-625.	4.0	58
14	IMI "Oral biopharmaceutics tools project" Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 626-642.	4.0	41